Related Experiment Video
Updated: Aug 15, 2026

Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
Pituitary apoplexy following adenoviral vector-based COVID-19 vaccination
Luca Roncati1, Antonio Manenti1
1Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Abstract:
Pituitary apoplexy (PA) may complicate the course of coronavirus disease 2019 (COVID-19), posing a potential threat to life. Among vaccines designed to prevent COVID-19, there are those adenoviral vector-based, such as Vaxzevria® (formerly COVID-19 Vaccine AstraZeneca). The product insert states that it can cause very rare coagulation disorders, in particular thrombosis with thrombocytopenia syndrome in some cases accompanied by bleeding, cerebrovascular venous or sinus thrombosis, and thrombocytopenia, including immune thrombocytopenia, also associated with bleeding. Here, we report the onset of PA after Vaxzevria® in a 28-year-old healthy Caucasian female, who experienced long-lasting tension-type headache, hyperprolactinemia and menstrual changes, without thrombocytopenia or thrombosis.
More Related Videos
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
08:17Direct Intrathecal Injection of Recombinant Adeno-associated Viruses in Adult Mice
Published on: February 15, 2019
Related Concept Videos
Viral Meningitis
Arboviral Encephalitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Brain Abscess l: Introduction
Cytotoxic Edema: Pathophysiology